Clinical Trial Update: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chidamide plus sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm; status not yet determined.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Neoplasm
• Neuroendocrine Tumor
• Neuroendocrine Tumors

Drugs mentioned

• Chidamide (chidamide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3 | Phase 2 | Status: UNKNOWN